Skip to content

Study · Randomized controlled trial · 2012

4 results

Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial.

García-Velasco JA, Kupesic S, Pellicer A, Bourgain C, Simón C, Mrazek M, Devroey P, Arce JC

Reproductive biomedicine online4 Nov 2011Cited by 3 (Europe PMC)

PMID22197127 (opens in a new tab)DOI10.1016/j.rbmo.2011.10.016 (opens in a new tab)PepBankPUB-22197127
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In oocyte donors, mid-luteal degarelix lowered FSH to 4.6 ± 2.3 versus 6.0 ± 1.8 IU/l with placebo (P<0.001).

    In plain wordsIn oocyte donors, mid-luteal degarelix lowered FSH compared with placebo before stimulation.

    Peptide
    Degarelix
    Outcome
    DecreaseSerum FSH at stimulation start
    Study

    n: not reported in source

    Comparator
    Placebo in the prestimulation cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    FSH
    4.6 IU/l
    degarelix-ML
    FSH
    6 IU/l
    placebo

    Source sentences

    Summary
    At start of stimulation, serum concentrations of FSH (4.6 ± 2.3 versus 6.0 ± 1.8IU/l), LH (2.7 ± 1.4 versus 4.7 ± 1.9IU/l) and oestradiol (87 ± 35 versus 129 ± 50pmol/l) were markedly lower (P<0.001) in the degarelix-ML group than in the placebo group.
    2 context sentences
    Summary · context
    Eighty-five oocyte donors were randomized to GnRH antagonist starting in the mid-luteal phase of the prestimulation cycle (degarelix-ML group), on stimulation day 1 (early follicular phase, degarelix-EF group) or day 6 (fixed protocol) (mid-follicular phase, ganirelix-MF group).
    Summary · context
    Subjects in the degarelix-EF and ganirelix-MF groups received placebo in the prestimulation cycle.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In oocyte donors, mid-luteal degarelix lowered LH to 2.7 ± 1.4 versus 4.7 ± 1.9 IU/l with placebo (P<0.001).

    In plain wordsIn oocyte donors, mid-luteal degarelix lowered LH compared with placebo before stimulation.

    Peptide
    Degarelix
    Outcome
    DecreaseSerum LH at stimulation start
    Study

    n: not reported in source

    Comparator
    Placebo in the prestimulation cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    LH
    2.7 IU/l
    degarelix-ML
    LH
    4.7 IU/l
    placebo

    Source sentences

    Summary
    At start of stimulation, serum concentrations of FSH (4.6 ± 2.3 versus 6.0 ± 1.8IU/l), LH (2.7 ± 1.4 versus 4.7 ± 1.9IU/l) and oestradiol (87 ± 35 versus 129 ± 50pmol/l) were markedly lower (P<0.001) in the degarelix-ML group than in the placebo group.
    2 context sentences
    Summary · context
    Eighty-five oocyte donors were randomized to GnRH antagonist starting in the mid-luteal phase of the prestimulation cycle (degarelix-ML group), on stimulation day 1 (early follicular phase, degarelix-EF group) or day 6 (fixed protocol) (mid-follicular phase, ganirelix-MF group).
    Summary · context
    Subjects in the degarelix-EF and ganirelix-MF groups received placebo in the prestimulation cycle.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In oocyte donors, mid-luteal degarelix lowered oestradiol to 87 ± 35 versus 129 ± 50 pmol/l with placebo (P<0.001).

    In plain wordsIn oocyte donors, mid-luteal degarelix lowered oestradiol compared with placebo before stimulation.

    Peptide
    Degarelix
    Outcome
    DecreaseSerum oestradiol at stimulation start
    Study

    n: not reported in source

    Comparator
    Placebo in the prestimulation cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Oestradiol
    87 pmol/l
    degarelix-ML
    Oestradiol
    129 pmol/l
    placebo

    Source sentences

    Summary
    At start of stimulation, serum concentrations of FSH (4.6 ± 2.3 versus 6.0 ± 1.8IU/l), LH (2.7 ± 1.4 versus 4.7 ± 1.9IU/l) and oestradiol (87 ± 35 versus 129 ± 50pmol/l) were markedly lower (P<0.001) in the degarelix-ML group than in the placebo group.
    2 context sentences
    Summary · context
    Eighty-five oocyte donors were randomized to GnRH antagonist starting in the mid-luteal phase of the prestimulation cycle (degarelix-ML group), on stimulation day 1 (early follicular phase, degarelix-EF group) or day 6 (fixed protocol) (mid-follicular phase, ganirelix-MF group).
    Summary · context
    Subjects in the degarelix-EF and ganirelix-MF groups received placebo in the prestimulation cycle.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In oocyte donors randomized to GnRH-antagonist regimens, the coefficients of variation of follicle size (36.7 ± 5.5% versus 39.2 ± 9.4%) were not significantly different.

    In plain wordsIn oocyte donors, follicle size variation was not significantly different between the compared groups.

    Peptide
    Degarelix
    Outcome
    No significant changeFollicle size variation
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Follicle size coefficient of variation
    36.7%
    first value in reported comparison
    Follicle size coefficient of variation
    39.2%
    second value in reported comparison

    Source sentences

    Summary
    The coefficients of variation of follicle size (36.7 ± 5.5% versus 39.2 ± 9.4%) were not significantly different.
    2 context sentences
    Summary · context
    Eighty-five oocyte donors were randomized to GnRH antagonist starting in the mid-luteal phase of the prestimulation cycle (degarelix-ML group), on stimulation day 1 (early follicular phase, degarelix-EF group) or day 6 (fixed protocol) (mid-follicular phase, ganirelix-MF group).
    Summary · context
    Subjects in the degarelix-EF and ganirelix-MF groups received placebo in the prestimulation cycle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT01709942

Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

Centre for Endocrinology and Reproductive Medicine, Italyn = 80Nov 2012 to Dec 2015

PCOS · OHSS · INFERTILITY

Trial pageClinicalTrials.govUpdated 27 Apr 2016
CompletedPhase 2Results postedNCT00434122

Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix

Ferring Pharmaceuticalsn = 85Mar 2007 to Dec 2007

Infertility, Female

Trial pageClinicalTrials.govUpdated 2 Jun 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.